Alzheimer’s Research Program Transforming Research Award | HT942525AZRPTRRA

Opportunity Information: Apply for HT942525AZRPTRRA

The Alzheimer’s Research Program (AZRP) Transforming Research Award is a discretionary grant opportunity from the U.S. Department of the Army, administered through the U.S. Army Medical Research Acquisition Activity (USAMRAA). It is designed to fund bold, non-incremental research that could meaningfully change the trajectory of Alzheimer’s disease and related dementias (AD/ADRD), with a clear emphasis on work aimed at reducing risk or preventing the development of these conditions rather than making small, stepwise advances. The program is positioned within the Science and Technology / Research and Development category (CFDA 12.420), and it is open to unrestricted applicants, meaning there are no special applicant-type limitations stated in the opportunity summary provided.

In terms of scientific scope, the award supports a broad range of approaches as long as they align with prevention or risk-reduction goals for AD/ADRD. Projects may use animal models, which could include mechanistic studies or preclinical intervention testing, and the opportunity also explicitly allows clinical research projects. A notable expectation embedded in the description is that proposed work should be “transforming” in nature, implying high-impact ideas, innovative designs, and a clear rationale for how the outcomes could shift current prevention strategies or understanding of risk in a way that standard incremental studies typically do not.

The solicitation includes a distinctive multi-PI structure through a Career Initiation or Transition (CIT) Partnership Option. Under this arrangement, multiple principal investigators can be tied to a single collaborative research effort. The process is somewhat unusual: only the initiating PI submits the pre-application, but each PI involved must submit a full application later. The opportunity also flags an important administrative risk in this structure: if the initiating or any partnering application is rejected or administratively withdrawn, the agency may withdraw all associated applications linked to that research project. Practically, this means teams considering the CIT Partnership Option need tight coordination, consistent eligibility and compliance across all PIs, and careful attention to submission requirements and timelines to avoid a single weak link affecting the entire partnership.

For any proposal involving clinical research, community collaboration is not optional; it is required. While the notice does not define the exact form this must take, the intent is typically that studies involving human participants should be shaped with meaningful input and partnership from relevant communities, which can improve recruitment, retention, cultural fit, and real-world usefulness of the research. Applicants planning clinical work should expect to describe how community partners will be engaged, what role they will play, and how their involvement will influence study design and execution.

Another major priority is leveraging existing resources and cohorts, especially those that help address critical health challenges and strengthen relevance to military health. This encouragement suggests the program values efficiency and real-world applicability, such as building on established longitudinal cohorts, existing biobanks, validated data resources, or ongoing collaborations that can speed progress and increase the likelihood that findings translate into settings that matter to service members, veterans, and military-connected populations. Proposals that can clearly connect their prevention or risk-reduction goals to military health needs, or that use cohorts and infrastructure with military relevance, may be better aligned with the stated intent.

The funding opportunity number is HT942525AZRPTRRA, and the listed closing date is August 29, 2025. The agency anticipates making about four awards, and the award ceiling is not specified in the provided source data, which usually means applicants will need to consult the full announcement for budget limits and any cost-related rules. Overall, the Transforming Research Award is geared toward ambitious AD/ADRD prevention-oriented research, with flexibility in model systems, a structured pathway for multi-PI partnerships, mandatory community collaboration for clinical studies, and a strong preference for leveraging existing cohorts and resources in ways that support military health relevance.

• The Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "Alzheimer’s Research Program Transforming Research Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on 2025-04-18.
• Applicants must submit their applications by 2025-08-29. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 4 candidate(s).
• Eligible applicants include: Unrestricted.

Apply for HT942525AZRPTRRA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: